Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.47 |
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2536076 | 1.00 | KCNH2 (0.47) | KCNH2DPP4DPP9DPP8DPP7 | |
| SCHEMBL2536081 | 1.00 | KCNH2 (0.47) | KCNH2DPP4DPP9DPP8DPP7 | |
| SCHEMBL2543611 | 1.00 | KCNH2 (0.47) | KCNH2DPP4DPP9DPP8DPP7 | |
| SCHEMBL2538154 | 1.00 | KCNH2 (0.47) | KCNH2DPP4DPP9DPP8DPP7 | |
| SCHEMBL2543425 | 1.00 | KCNH2 (0.47) | KCNH2DPP4DPP9DPP8DPP7 | |
| SCHEMBL2538157 | 1.00 | KCNH2 (0.47) | KCNH2DPP4DPP9DPP8DPP7 | |
| SCHEMBL2543422 | 1.00 | KCNH2 (0.47) | KCNH2DPP4DPP9DPP8DPP7 | |
| SCHEMBL16649914 | 1.00 | KCNH2 (0.47) | KCNH2DPP4DPP9DPP8DPP7 | |
| SCHEMBL2533871 | 1.00 | KCNH2 (0.47) | KCNH2DPP4DPP9DPP8DPP7 | |
| SCHEMBL2543613 | 1.00 | KCNH2 (0.47) | KCNH2DPP4DPP9DPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094267-B1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-04-22 | — | — | EP | claimed |
| EP-2094267-B1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-04-22 | — | — | EP | disclosed |
| US-8044044-B2 | 4-(1-amino-ethyl)-cyclohexylamine derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-25 | — | — | US | disclosed |
| US-20100029623-A1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029623-A1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | AHR, KRAS, CNKSR1 | KCNH2 296/4885DPP4 3755/4885DPP9 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.